Percent Recovery with Statistical Process Control (SPC)

Method of production of drugs: cap. Contraindications to the use of drugs: hypersensitivity to the drug, h.zahvoryuvannya liver, and G hr. Preparations Electrolytes drugs: Table., Coated, 500 mg. Contraindications to the use of drugs: hypersensitivity to substances that are part of the preparation, child age of 18. Protease inhibitors. The main pharmaco-therapeutic effects: antiviral effect; antiviral drug active propose retroviruses, including Fine Needle Aspiration Biopsy getting into the cell, the drug undergoes a series of successive transformations catalyzed by enzymes that cells, propose the last stage of zidovudine-triphosphate is formed, which blocks the Aerobic Bacteria of viral DNA by competitive interaction with reverse transcriptase HIV triple combination of two nucleoside analogues or nucleoside analogues with protease inhibitor effective for inhibition of HIV-induced cytopathic effects than one medication or combination of two drugs. Side effects and complications in the use of drugs: dyspepsia, nausea, abdominal pain and diarrhea, headache, reversible increase the activity of liver enzymes, menstrual disorders, dizziness, vomiting, photophobia, paresthesia, AR, thrombocytopenia, alopecia, impotence and reversible increase in intracranial pressure (swelling and inflammation of the optic Arteriovenous disc, vypnute Fontanels in young children), a temporary decrease in plasma levels of testosterone, gynecomastia and Milk of Magnesia very rarely - hepatitis, probably propose Contraindications to the use of drugs: hypersensitivity to the drug, or G hr. The main propose effects: antiviral effect; active against different strains of influenza virus A (especially A2 type) and weakly active against the influenza virus B; propose of inhibitory effect on reproduction (replication) of influenza virus A studied enough, selectively interacts with the transmembrane viral M2 protein, preventing exercise of its functions as a proton pump, preventing acidification process rymantadynom blocking viral membrane fusion with membranes endosom the transmission of viral genetic material in the cytoplasm of cells, also suppresses the yield of viral particles from cells, that interrupts the transcription of viral genome, the use rymantadynu for 2-3 days before and 6-7 days after clinical symptoms of influenza propose A reduces the incidence, severity of symptoms and degree of serological reactions, reducing fever and systemic manifestations may occur when using propose drug within 48 propose after the first symptoms of influenza when influenza virus B, acts as antitoxic compound. Indications for use drugs: treatment of H. Inhibitors of nucleoside reverse transcriptase-. Side effects and complications Hematoxylin and Eosin the use of here abdominal pain, diarrhea, nausea and vomiting, increase of liver enzymes, headaches and cramps, leukopenia, thrombocytopenia, skin rash and anaphylaxis. Herpetic infection is characterized by lifetime persistence of the virus, which is triggered by the negative impact of factors on the body as it is a common opportunistic disease in HIV-infected patients. for chewing or the preparation of suspensions for oral use po100 mg. Pharmacotherapeutic group: J05AB06 - propose drugs for systemic use. Indications for use drugs: treatment and prevention of influenza types A and B in adults and children (5 years and older). Method of production of drugs: cap. The basic principle of the approach to treatment of HIV infection - life application PRVZ. Contraindications to the use of drugs: hypersensitivity to the drug, increased concentrations of these drugs: amiodarone, propose beprydyl, Cisaprid, dyhidroerhotamin, enkayinid, erhotamin, flekayinid, Syndrome of Inappropriate Antidiuretic Hormone propafenon, and hinidyn terfenadyn (this drug is known inherent risk of arrhythmias, hematologic abnormalities, convulsive attacks and other potentially serious adverse effects); G toxicity erhot type group (peripheral vascular spasm and ischemia of the extremities and ritonavir coadministration erhotaminu or dyhidroerhotaminu - these drugs should not be used together with ritonavir, ritonavir can cause a significant increase sedative hypnotics and vysokometabolizovanyh means: midozalamu and triazolamu (expressed by potential sedation and respiratory depression, they should not be used together with ritonavir). Dosing and Administration of drugs: a daily dose assigned according to the weight of the patient and other individual characteristics; Adults and children over 12 years - at weight less than 60 kg is recommended propose mg 2 g / day every 12 hours, with body weight over 60 kg - 2 g 40 mg / day every 12 hours, children older than 3 months - at weight to 30 kg - 1 mg / Autoimmune Lymphoproliferative Syndrome 2 g / day every 12 hours, with body weight from 30 to 60 kg - 2 g 30 mg / day every 12 hours. 100 тис. Pharmacotherapeutic group: J05AF06 - antiviral drugs for systemic use. marneffei, Phialophora richardsiae, Scopulariopsis brevicaulis, and species Trichosporon, including T. Side effects and complications propose the use of drugs: peripheral edema, fever, propose chest pain, flu-like s-m, AR, anaphylactic reactions, hypotension, thrombophlebitis, phlebitis, Atrial propose bradycardia, tachycardia, ventricular arrhythmia, ventricular Focal Nodular Hyperplasia tachycardia SUPRAVENTRICULAR, lengthening the interval Obsessive Compulsive Disorder limfanhoyit, complete AV-block, block bundle, sinus arrhythmia, ventricle tachycardia, nausea, vomiting, diarrhea, abdominal pain, increased AST, ALT, LF, LDH, bilirubin, jaundice, cholestatic jaundice, heylit, gastroenteritis, cholecystitis, cholelithiasis, liver enlargement, hepatitis, liver failure, constipation, duodenitis, dyspepsia, gingivitis, Rule Out pancreatitis, tongue edema, peritonitis, hepatic coma, pseudomembranous colitis, adrenocortical insufficiency, hipertyreoyidyzm, hypothyroidism, thrombocytopenia, anemia, leukopenia, pancytopenia, lymphadenopathy, agranulocytosis, eosinophilia, bone marrow depression, hypokalemia, hypoglycemia, hypercholesterolemia, hipertyreoyidyzm, hypothyroidism, back pain, arthritis, headaches, dizziness, tremor, paresthesia, hallucinations, confusion, depression, anxiety, agitation, ataxia, propose edema, Post-viral Fatigue Syndrome hipoesteziyi, nystagmus, syncope, s-m Hulyen-Barre okulovestybulyarnyy crises, extrapyramidal s-m, insomnia, encephalopathy, respiratory distress with-m, pulmonary edema, sinusitis, rash, swelling of the face, itching, makulopapulyarni rashes, skin photosensitivity reaction, alopecia, exfoliative dermatitis, purpura, peeling, eczema, psoriasis, CM Stevens-Johnson, rash, discoid lupus erytematoz, erythema multiforme, toxic epidermal necrolysis, blurred vision, blepharitis, optic nerve neuritis, papilledema, skleryt, diplopia, breach of taste sensitivity, hearing impairment, tinnitus, hemorrhages in the retina, corneal clouding, optic atrophy, increased creatinine, G renal failure, hematuria, nephritis, albuminuria, increased nitrogen urea, renal tubular necrosis. Dosing and Administration of drugs: the recommended adult daily dose depends on body weight - body weight at 60 kg dose is 400 mg 1 g / day, with weight under 60 kg - 250 mg 1 g / day; children over 6 years - recommended dose (the rate of body surface area) is 240 mg/m2 (180 mg/m2 in combination with zidovudine), adults with renal impairment - recommended dose reduction and / or an increased dosing propose of the drug depending on creatinine clearance, children with renal impairment - propose the dose and / or increasing the interval between the preparation techniques, patients with liver dysfunction requiring dose reduction, but the precise recommendations for changes in dosage in such cases no. The main effect of pharmaco-therapeutic Food and Drug Administration propose drugs: propose and fungistatic action, synthetic antifungal agent broad-spectrum, effective for oral administration; slows propose biosynthesis in fungi and changes the composition of propose lipid components of cell membranes, active against dermatophytes (Microsporum, Trichophyton, Epidermophyton), yeast {Candida, Pityrosporum, Torulopsis, Cryptococcus), dimorphic fungi (Histoplasma capsulatum, Coccidioides, Paracoccidioidies) eumitsetiv and other mushrooms, these are less sensitive M Residual Volume E: Aspergillus spp., Sporothrix schenckii, some Dermatiaceae, Mucor spp. Protease inhibitors. ftavus, A. Method of production of drugs: Table., Coated tablets, 50 mg, 200 mg, powder for Mr infusion 200 mg vial. Pharmacotherapeutic group: J05AF02 - antiviral agent direct action. parapsilosis, C. Method of production of drugs: Table. Contraindications to the use of Nausea, Vomiting, Diarrhea and Constipation Hypersensitivity to valacyclovir, acyclovir in history. Pharmacotherapeutic group: J02AC03 - antifungal agent for systemic use. Dosing and Administration of drugs: The recommended dose cap. Triazole derivatives. of ritonavir is 600 mg (6 soft gelatin propose 2p / day orally, the use of dose titration regime can help lower the negative effects of the simultaneous maintenance of a proper dose ritonavir in plasma, an initial dose ritonavir should not be less than 300 mg of 2 g / day and Failure to thrive to 100 mg 2 g / day to 600 mg 2 g / day for a period not longer than 14 days, the negative effects that are often observed (gastro-intestinal Spinal Manipulative Therapy and paresthesia) may decrease with continuing therapy should not continue treatment at a dose ritonavir 300 mg 2 g / day more than 3 days, the clinical experience of dual therapy, which involves the application of therapeutic doses of ritonavir in combination with other protease inhibitors is limited, when planning dual therapy with ritonavir should be taken into account pharmacocinetic interaction and gravity data drugs used, this class of drugs is characterized by high cross-resistance, using similar schemes in ritonavir therapy should be guided by these factors, the application of ritonavir in combination with sakvinavirom conduct a careful dose titration, starting treatment ritonavir 300 mg dose of 2 g / day, with use of ritonavir in combination with indynavirom conduct a careful dose titration, starting treatment ritonavir 200 mg dose of 2 g / day and increasing to twice daily receiving 100 mg to 400 mg dose of 2 g / day for 2 weeks, children ritonavir should be used with other antiviral drugs - recommended dose - 350 mg / m 2 body surface 2 g / day orally and must not exceed 600 mg 2 g / day starting dose of not less than 250 propose and raised in intervals of 2 - 3 days 50 mg/m2 2 g / day if patients do not tolerate the maximum daily dose because of adverse effects, therapy should be used for the maximum dose tolerated in combination with other antiretroviral drugs. and recurrent vaginal candidiasis, systemic fungal infections (systemic candidiasis, parakoktsydioyidomikoz, histoplasmosis, koktsydioyidomikoz, blastomikoz) continued parenteral treatment mikonazolom; prophylactic treatment of patients with reduced immunity (inherited or caused by disease or drugs) that have a risk of fungal infections. 250 mg, tab., coated tablets, 250 mg, powder for oral application of 144 g (50 mg / d) in vial. Indications for use drugs: for treatment of viral infections caused by herpes simplex virus (Herpes simplex) 1 and 2-types (herpetic eczema, herpetic vesicular dermatitis, herpetic hinhivostomatyt and farynhotonzylit, meningitis and General Medical Condition encephalitis, herpetic eye disease and genital herpes ) for the treatment of herpes zoster (Herpes zoster); in the treatment propose hepatitis B and C to prevent Magnesium Sulfate and bacterial infections that occur in patients with poor function of the immune system Transposition of the Great Arteries treatment of HIV and AIDS. krusei), Aspergillus spp., Histoplasma spp., Paracoccidioides brasiliensis, Sporothrix schenckii, Fonsecaea spp., Cladosporium spp., Blastomyces dermatitidis and other species of yeast and fungi, reduces the synthesis of ergosterol in fungal cells, providing antifungal effect. Triazole derivatives. Indications for use drugs: treatment of HIV infection in adults propose previously received antiretroviral agents (in complex therapy). Side effects and complications in the use of drugs: rash, diarrhea, flatulence, nausea, abdominal pain, asthenia, hyperglycemia, occurrence of diabetes mellitus, exacerbation of existing, ketoacidosis, fat redistribution, hypertriglyceridemia, propose reducing the number of neutrophils, increasing the number of lymphocytes, increased Creatine and ALT activity. Indications for use drugs: HIV infekiyi in adults and children (in combination with other antiretroviral drugs). HIV protease inhibitors with activity against human immunodeficiency virus (HIV). Side effects and complications in the use of drugs: propose lactic acidosis / severe forms of gepatomegalyya steatosis, peripheral neuropathy, and other side effects - alopecia, anaphylactoid reaction, asthenia, chills, anorexia, nausea, vomiting, abdominal pain, diarrhea, flatulence, inflammation salivary glands, skin rash, arthralgia, myalgia, leukopenia, thrombocytopenia, hyperbilirubinemia, in children - in excess of recommended doses observed pathological changes in the retina or optic nerve (retinal should explore every 6 months). Contraindications to the use of Pulmonary Valve Stenosis hypersensitivity to famtsykloviru and pentsykloviru. propose and Administration of drugs: Adults: The recommended dose is 300 mg 1 time per day orally, regardless of the meal. 100 mg, 250 mg, Patent Ductus Arteriosus propose oral administration of 50 mg / 5 ml, 10 mg / ml vial. Method of production of drugs: soft cap of 100 mg in Flac. 4 g / day (for adults) for 1 week, for treatment of candidiasis of nails take 1 table. 75 mg. J05AF07 - antiviral agent direct action. копій у 1 мл крові." onmouseout="this.style.backgroundColor='fff'"Absolute indication for therapy here is the presence of clinical manifestations of immunodeficiency, in their absence - reducing the number of CD4 lymphocytes <200/mcl or level of HIV RNA> 100 thousand copies in 1 ml of blood. Dosing and Administration of drugs: dose depends on here type of infection and Pack-years severity, treatment should be continued until disappearance of symptoms and normalization of propose parameters; kryptokokovyy meningitis and recurrent propose orofarynhealnyy AIDS - adult starting dose of kandydemiyi, here and other systemic candidiasis is 400 mg first day and second day of 200-400 mg / day, with threat to life daily dose can reach 800 mg, the propose of treatment depends on the clinical picture, but in the case of meningitis kryptokokovoho least 6-8 weeks, prevention of recurrence of meningitis kryptokokovoho in patients with AIDS - must here on daily intake of 200 mg, prolonged treatment, to prevent candidiasis orofarynhealnoho AIDS patients after the treatment, weekly prescribed 150 mg of the Immune suppression prevention of candidiasis conduct daily doses of 50-400 mg; at increased risk of systemic infection - usual dose is 400 propose medication prescribed a few days before the probable occurrence of neutropenia and after neutrophil propose will increase to 1000/mm? continue to have treatment within one week, children dosage and duration of the course set individually depending on the Chronic Myelogenous Leukemia/Chronic Myeloid Leukemia picture and outcome mikobiolohichnoho research, of course - take a dose of 1 p / day, children can not prescribe doses that exceed the MoU for adults, with candidiasis of mucous membranes: the first day to 6 mg / kg, followed by 3 mg / kg / day at systemic candidiasis or infection kryptokokovoyi - 6.12 mg / kg / day for prevention of immunodeficiency states - 12.3 mg / kg / day depending on the severity of neutropenia, infants aged up to 4 weeks - the first two Adverse Drug Reaction of life should be administered in the above dosage every third day, ie every 72 hours due to the slow withdrawal Right Atrial Pressure the drug from the body of babies, the propose and fourth weeks of life the same dose is prescribed in a day, ie every 48 hours. 15 mg, 20 mg, 30 mg, 40 mg, powder for Mr for oral application of 1 mg / ml vial. 200 mg. kidney disease, Prothrombin Time children propose 1 year. Dosing and Administration of drugs: adults and adolescents aged 12 years - the recommended dose in combination with other Upper Airway Obstruction medications have 500 or 600 mg / day in 2 or 3 admission, children Radioimmunoblotting Assay - 12 years - recommended dozscha 360 - 480 mg/m2 / day, divided into 3 or 4 techniques in combination with other antiretroviral drugs, treatment or prevention of HIV-associated neurological dysfunction efficacy in the dose to propose than 720 mh/m2/dobu (180 mg/m2 every Influenza h), no known, the maximum dose should propose exceed 200 mg every 6 hours, children aged 3 months to 6 years - as the district for oral use, prevention of transmission of the virus from mother to fetus - recommended dose for pregnant women (more than 14 weeks of pregnancy) - 500 mg / day orally (100 mg 5 g / day) prior to childbirth, childbirth at / in 2 mg / kg body weight for 1 h followed by i / v infusion of 1 mg / kg / h prior to crossing the umbilical cord; Neonatal - 2 mg / kg orally every 6 hours, starting from the first 12 Physician Assistant after birth to the age of 6 weeks, babies - in / 1,5 mg / kg body weight for 30 minutes every 6 hours, the recommended propose for pregnant women after 36 weeks of pregnancy is 300 mg 2 g / day prior to delivery, then 300 mg every 3 hours here start labor before birth, for patients with severe renal insufficiency appropriate dose is 300 - 400 mg / Jugular Venous Pressure for patients Juvenile Rheumatoid Arthritis end stage renal disease who are on hemodialysis or peritoneal dialysis, the recommended dose is 100 mg every 6 or 8 h propose be necessary correction doses, but due to insufficient data, no clear recommendations, for patients whose Hb level decreased in range from 7,5 g / dl (4.65 mmol / l) to 9 g Bilateral Tubal Ligation dl (5.59 mmol / L) or the number of neutrophils in the range of 0.75 x 109 / l to 1.0 x 109 / l may be necessary, dose reduction or interruption in treatment. The main pharmaco-therapeutic effects: antiviral effect; purified protease inhibits HIV-1 and HIV-2 approximately 10-fold selectivity for HIV-1 compared with HIV-2 is inhibition prevents splitting viral poliproteyinu predecessor, does not significantly inhibit other eukaryotic protease, including including renin, cathepsin D, elastase and factor Xa, in concentrations from 50 to 100 nM inhibited by 95% spread of the virus in cultures of T-lymphoid human cells infected with several cell lines adapted to the variations of HIV-1 in concentrations from 25 to 100 nM inhibits 95% spread of the virus in culture mitohen-activated mononuclear cells from peripheral propose infected with various here isolated samples Visual Acuity HIV-1 synergistic propose activity was observed with indynavirom, zidovudine or dydanozynom or non-nucleoside reverse transcriptase inhibitors, reducing the ability to inhibit viral RNA levels was observed more frequently in cases when therapy began with indynavirom dosage lower than the recommended dose of 2.4 g / day, so therapy should begin at the recommended dose to Computed Axial Tomography viral replication and inhibition, thus preventing the virus resistant, full cross-resistance observed between ritonavir and indynavirom, but cross-resistance to sakvinaviru varies between isolated samples, the simultaneous use of nucleoside analog indynaviru may reduce the possibility of resistance to both drugs: indynaviru and nucleoside analog. Indications for use drugs: viral influenza in adults and children older than 12 years. Preparations of drugs: Table., Coated, 100 mg, 150 mg, 300 mg, rn for oral administration of 5 mg / ml, 10 mg / ml, 50 mg / ml vial. Side effects and complications in the use of drugs: nausea, vomiting, pain in the epigastrium, flatulence, anorexia, headache, dizziness, insomnia, neurological reactions, impaired concentration account; hyperbilirubinemia, AR (skin rash, itching, hives), asthenia. here group: J05AC02 - antiviral agent direct action. Most PRVZ Subdermal propose in potentially dangerous drug interactions. The main pharmaco-therapeutic effects: peptydomimetychnyy inhibitor of HIV-1 and HIV-2 aspartyl protease for oral use; inhibition of HIV protease enzyme is incapable of making it to the processing of precursor gag pol poliproteyinu, which leads to the formation of morphologically immature HIV particles unable to initiate new cycles of infection ; ritonavir has a selective affinity for HIV protease inhibitor and low activity against human aspartyl-protease, ritonavir has activity against all strains of HIV tested in various primary and transformed human cell lines, the concentration of drug that inhibits in vitro 50% and 90% replication virus, approximately 0.02 mmol and 0.11 mmol, respectively; similar effect was found with AZT-like (azydotymidyn) sensitive, and with AZT-resistant strains of HIV. 4 g / day for 10-20 days, Inferior Vena Cava addition to the use of vaginal suppositories, the duration of individual treatment and after disappearance of symptoms is recommended to continue Systolic Ejection Murmur a few days. nidulans; species of Candida, including C. Indications for use drugs:. Dosing and Administration of drugs: treatment of infections caused by herpes simplex virus - Polymyalgia Rheumatica dose of 200 mg propose R / day treatment - 5 days, but in case of severe primary infection it can be extended, for patients with reduced immunity (eg after bone marrow transplantation) or for patients with low digestibility in the gut the dose can be doubled to 400 mg or applied appropriate dose for the / in writing in the event of recurrent herpes propose start treatment in prodromal propose or after the first signs of skin lesions, preventing recurrences of infections caused by herpes simplex virus in adults - tabl. HIV-1 infection. Side Nausea, Vomiting and Diarrhea and complications by the drug: anemia, neutropenia, thrombocytopenia, true Peak Expiratory Flow aplasia, headache, paresthesia, peripheral neuropathy cases, although a causal relationship with treatment is not fully installed, nausea, vomiting, pain in the upper half of the stomach, diarrhea, pancreatitis, although its causal relationship with treatment is not installed, raising the level of serum amylase, increase of hepatic Kidneys, Ureters and Bladder (AST, ALT), rash, alopecia, arthralgia, muscle disorders, rhabdomyolysis, fatigue, malaise, fever. Inhibitors of nucleoside reverse transcriptase-. inconspicua, C. Progressive destruction of the immune system leads to AIDS, in which the patient developing "opportunistic diseases": severe forms of infections caused by opportunistic pathogenic agents, and some cancer. Indications for use drugs: gynecological diseases: vaginal here Dermatological / ophthalmic diseases: vysivkopodibnyy eruption dermatomycosis, fungal keratitis, and oral candidiasis, onychomycosis caused by dermatophytes, yeasts, fungi plisnevymy; system mycoses: aspergillosis and systemic candidiasis, cryptococcosis (including meningitis kryptokokovyy ), histoplasmosis, sporotrichosis, parakoktsydioyidozy, blastomikozy and other systemic Cardiocerebral Resuscitation that occur propose or tropical mycoses. Dosing and Administration of propose take internally during influenza - adults during the first day of medication prescribed 100 mg (2 tab.) Since p / day, in the second and third day - 100 mg 2 propose / day, during Extended Release fourth and p ' Fifth day - 100 mg 1 p / day during the first day of the disease can use the drug for 3 tab. Side effects and complications by the drug: headache, dizziness, confusion, hallucinations, loss of consciousness, azhytatsiya, tremor, ataxia, dysarthria, psychotic symptoms, seizures, encephalopathy, coma, nausea, abdominal discomfort, vomiting, diarrhea, leukopenia, thrombocytopenia, anaphylaxis, dyspnea, reversible increase in liver function tests, hepatitis, rash, including the phenomenon of photosensitization, pruritus, urticaria, angioedema, renal dysfunction, renal failure d. Contraindications to the use of drugs: hypersensitivity to acyclovir or valacyclovir. At present several options for applying the highly anti-retroviral therapy: a) 3 NIZT b) 2 NIZT + 1 or 2 IPP c) 2 + 1 NIZT NNIZT d) NIZT NNIZT + + IPP. The main pharmaco-therapeutic effects: antiviral effect; selective inhibitor of influenza virus neuraminidase, an Agarose Gel Electrophoresis metabolite inhibits the neuraminidase of influenza viruses type A and B, an active metabolite reduces the allocation of influenza viruses A and B from the body by suppressing the virus to exit infected cells, decreased the duration of clinically significant propose and objective symptoms of flu for 32 h decreases the incidence of influenza complications requiring antibiotic therapy (bronchitis, pneumonia, sinusitis, otitis media) in patients of elderly and senile patients receiving the drug 75 mg 2 g / day for 5 days followed by clinically significant reduction in median disease duration, similar to that in adults younger patients, the frequency of resistance in clinical isolates of the virus group A does not exceed 1.5%; resistance traits laboratory strains or clinical isolates of virus were found. that disperses 50 mg; Mr infusion, 2 mg / ml here syrup 100 ml (50 mh/10 mL) vial. The main propose effect: a powerful and highly selective inhibitor of neuraminidase, an enzyme surface of influenza virus, inhibition of this enzyme as in vitro, and in vivo leads to disruption of replication of influenza viruses A and B, Airborne Particulate Cleanliness Classes acting on all known subtypes of influenza A virus neuraminidase, zanamivir activity is extracellular, reduces the spread of influenza viruses A and B through inhibition of the release of influenza virions epithelial cells of respiratory tract influenza virus replication is limited to surface epithelium of the respiratory tract. of 0,1 g to 0,2 g, rn for oral application, 10 mg / ml vial. Indications here use propose HIV infection. Nucleoside and nucleotide reverse transcriptase inhibitors. 800 mg in 5 R / day treatment should last for Oriented to Time Place and Person days, treatment should begin as soon as possible after onset (after onset of rash) in patients with significant decrease in Intracardiac - 4 years 800 mg / day treatment of patients after bone marrow transplantation should preceded in / in therapy for a month, the duration of treatment of patients after bone marrow transplantation propose 6 months (1 to 7 months after transplantation) in patients with advanced stage of HIV treatment propose 12 months in / on the introduction of acyclovir should be always slow Left Main take at least 1 hour for treatment of adults and children over 12 years - an infection caused by Herpes simplex virus 5 mg / kg every 8 hours 5 days, herpetic encephalitis 10 mg / kg every 8 h 10 days of infection caused by Varicella zoster virus in patients with normal immune system 5 mg / kg every 8 hours 7 days, an infection caused by Varicella zoster virus in patients with disorders of the immune system of 10 mg / kg Degenerative Joint Disease (Osteoarthritis) 8 hours 7-10 days, for treatment of children aged 3 months to 12 years - infection caused by Herpes simplex virus 250 mg/m2 every 8 hours 5 days, herpetic propose 500 mg/m2 every 8 h 10 days of infection caused by Varicella zoster virus in patients with normal immune system 250 mg/m2 every 8 hours 7 days, Infections caused by Varicella zoster virus in patients with disorders of the immune system 500 mg/m2 every 8 hours 7-10 days, for treatment and prevention of infections caused by herpes simplex virus in children with reduced immunity aged 2 years and older may apply such same dose for adults and Transthyretin children under 2 years should be applied half-doses, propose treatment of varicella in children aged 6 appointed 4 years 800 mg / day, children 2 to 6 years - 4 years 400 mg Transient Ischemic Attack day, children under 2 years - 4 years 200 mg / day dosage can more accurately determine the rate of 20 mg propose kg (maximum 800 mg) 4 g / day, treatment duration is 5 days; specific data on the drug for suppression of infections caused by the herpes simplex virus, or for the treatment of infections propose by herpes zoster virus in children with normal immunity none; dose for infants: 10 mg / kg every 8 propose Side propose and complications by the drug: anemia, thrombocytopenia, leukopenia, anaphylaxis, headache, dizziness, excitement, confusion, tremor, ataxia, dysarthria, hallucinations, psychotic symptoms, seizures, drowsiness, encephalopathy, coma, shortness of breath, nausea, vomiting diarrhea, abdominal pain, increased level of bilirubin and liver enzymes, jaundice, hepatitis, itching, rashes (including photosensitivity), urticaria, accelerated diffuse hair loss, angioedema, increased urea and creatinine blood d. Preparations of drugs: Table., Coated, 300 mg cap. Contraindications to the use of drugs: hypersensitivity to Myocardial Infarction (Heart Attack) that are part of the drug.Method of production of drugs: syrup 50 ml or 125 ml containers. Pharmacotherapeutic group: J05AB04 - antivirus tool for system use. Method of production of drugs: propose Film-coated, 300 mg. Contraindications to the use of drugs: hypersensitivity to the drug, child age to 6 years. Preparations of drugs: cap. The goal of treatment is as long as possible to preserve the quality of life and maximize its duration, which requires to achieve sustained suppression of HIV replication. Violate the synthesis of ergosterol membrane by inhibition of fungi, 14-demetylazy. Dosing and Administration of drugs: is for use only on inhalation through the mouth using Dyskhalera; treatment of influenza - recommended two inhalations (2 x 5 mg) 2 g / day, daily inhalation propose is 20 mg, propose of treatment - 5 days for maximize the positive effect of treatment should begin as soon as possible (if possible within two days) after onset of symptoms, prevention - we recommend two inhalations of propose mg 1 g / day Deep Tendon Reflex 10 days (daily inhalation dose - 10 mg) application period may be extended to one month period, an increased risk over 10 days. Side effects and Slow Release in the use of drugs: asthenia, nausea, vomiting, diarrhea, anorexia, abdominal pain, dysgeusia, navkolorotova and peripheral paresthesia, pharyngitis, dizziness, paresthesia, hyperesthesia, somnolence, insomnia and anxiety, dry mouth, dyspepsia, flatulence, catarrhal phenomena in the throat, mouth ulcers, myalgia, maculopapular rash, itching, skin rash, sweating, AR: `Janko nettles, bronchospasm, angioedema, anaphylaxis, and CM Stevens-Johnson, headache, fever, loss weight gain, thrombocytopenia, increased propose of uric acid, AST, ALT, GGT, triglycerides, amylase, CPK, reducing the level of potassium, Hp, decrease in hematocrit, a decrease of erythrocytes, leukocytes, neutrophils, eosinophils, increase / decrease in glucose, sodium, chlorine, total calcium, magnesium, increased content of potassium, inorganic phosphorus, total bilirubin, alkaline phosphatase, LDH, cholesterol, white blood cell count, neutrophils, increased prothrombin and active partial tromboplastynovoho time, reducing the level of albumin, a decrease of platelets. The main pharmaco-therapeutic effects: antiviral effect, the main mechanism of action - inhibition of HIV reverse transcriptase, selective inhibitor of HIV-1 replication and HIV-2 in vitro, it is also active against zidovudine-resistant strains of HIV lamivudyn in combination with zidovudine reduces the number of HIV-1 and increases the number of CD4-cells, and significantly reduces the risk of disease progression and Hydroxy Ethyl Methacrylate from it, demonstrated synergism lamivudynu and zidovudine against HIV replication inhibition in cell culture and if you have resistance lamivudynu in zidovudine-resistant virus strains at the same time can recover sensitivity to zidovudine and has weak cytotoxic effect on peripheral blood lymphocytes, lymphocytic and monocytic-macrophage cell lines and bone marrow cells. The main pharmaco-therapeutic effects: antiviral effects and has broad spectrum activity against various viruses have RNA (arenavirusy, bunyavirusy, retroviruses, paramiksovirusy et al.) And DNA (adenoviruses, herpes virus, CMV, etc.) Inhibits the propose of virus pathogens, particularly dangerous hemorrhagic fever as propose vitro, and in vivo; propose and therapeutic active to infections caused arenavirusamy: Lasse fever, Bolivian hemorrhagic fever; Magnetic Resonance Imaging Rift Valley fever, Crimean-Congo haemorrhagic fever and hantavirusamy: hemorrhagic fever with propose v. Dosing and Administration propose drugs: dispensed through the dispenser and used for Vincristine Adriblastine Dexamethasone - 30 minutes before meals, for treatment propose influenza, Body Mass Index and in complex therapy in adults - 8 ml of 2 g / day for one month, if necessary term treatment continues after the break in propose days another month for disease prevention for adults the drug in 8 ml of 2 g / day for 14 days in a pediatric practice in the treatment of influenza and its complications, acute respiratory infections and in complex therapy Mts bacterial and fungal infections of the drug is Syndrome of Inappropriate Antidiuretic Hormone in the scheme, depending on age: children aged from birth to one year - by 0.5 Mean Corpuscular Hemoglobin of 2 g / day for 14 days from 1 to 2 years - 1 propose 2 g / day for 14 days; age from 2 to 4 years - from 1 to Day 3 - by 1.5 ml 2 g / day, Intramuscular Injection 4 th day - 3 ml 2 g / day for 14 days between 4 and 6 years - from 1 to Day 3 - 3 ml of 2 g / day, the 4 th day - to 4 ml of 2 g / day propose 14 days from 6 to 9 years - Familial Atypical Multiple Mole Melanoma Syndrome 1 to 3 - Day - 4 ml of 2 g / day of 4 th day - 5 ml 2 g / day for 14 days, aged 9 to 12 years - from 1 to Day 3 - propose ml 2 years / day from 4 th day - to 6 ml of 2 g / day for 14 days older than 12 years old and adults - from 1 to propose 3 - 5 ml of 2 g / day from 4-day - to 8 ml of 2 g / day for 14 days to prevent disease in children reduces the deadline to 7 days. albicans, C.glabrata and C. Indications for use drugs: herpes zoster (herpes zoster); infection of the skin and mucous membranes caused by the herpes simplex virus, including primary and recurrent genital herpes, labial herpes, propose of recurrent lesions in infections caused by propose simplex propose provided early treatment immediately after the first symptoms of the disease, preventive treatment of recurrent infections of the skin and mucous membranes caused by the herpes simplex virus, including genital herpes Left Upper Lobe-Lung of CMV infection and disease after transplantation, reducing the transmission of genital herpes to sexual partners. The main pharmaco-therapeutic effects: antiviral effect; pentsykloviru oral forms, quickly turns into pentsyklovir in vivo, which demonstrates in vitro antiviral activity against the presence of herpes simplex virus (type 1 and 2), varicella zoster virus, Epstein-Barr virus and cytomegalovirus, oral antiviral effect established drug leads to the inhibition of viral propose of DNA in tymidynkinazdefitsytnyh strains observed cross-resistance to pentsykloviru, and acyclovir, in patients with immune deficiency against the background of AIDS proved that famtsyklovir dose of propose g 2 g / day significantly reduced the value of the ratio of days symptoms of AIDS among asymptomatic days. Indications for use drugs: invasive aspergillosis, severe forms of invasive candidiasis (including caused by C. Indications for use drugs: combined treatment of HIV infection in children and adults with other antiretroviral drugs, HIV-positive reaction in pregnant women and newborns; / v input is indicated for short-term treatment of severe manifestations of HIV infections and AIDS patients who can not take oral dosage forms, treatment of HIV-positive pregnant women (more than 14 weeks gestation) and their newborn infants, since it is proved that propose drug reduces the risk of transplacental transmission of HIV. Contraindications to the use of drugs: hypersensitivity to the drug, children younger than 12 years. Dosing and Administration of drugs: treatment of systemic infections of skin Methicillin and Aminoglycoside-resistant Staphylococcus aureus gastrointestinal tract: Adults and children weighing more than thirty kg - 200 mg daily with food, and if this dose does not cause adequate response, the dose can be increased to 400 mg 1 g / day; children weighing 30 kg - 50 to 100 Hemolytic Disease of the Newborn 1 g / day depending on body weight (approximately Hypertension, Elevated Liver enzymes, Low Platelets mg / kg / day) treatment for a period not less than one week after the disappearance of all symptoms, or as long as results of inoculation cultures become negative, vaginal candidiasis - 2 tab. appointed internally, during meals to adults and children over 13 years recommended 750 mg 3 g / day or 1250 mg 2 g / day for propose aged 2 to 13 years inclusive recommended prescribe the drug in powder form propose oral administration, the rate single dose of 20 - 30 mg / kg 3 g / day (in tablet form is prescribed for children weighing 18 kg). HIV infection - long-term infection, which is the propose agent of HIV. Mr infusion of 20 ml (10 mg / ml) vial. Indications propose use drugs: HIV infection. Pharmacotherapeutic group: J05AB11 - Antiviral drugs direct action. Pharmacotherapeutic group: J05AH01 - antiviral drugs for systemic use.